Enable Accessibility Enable Accessibility

Our Products

Shire is now part of Takeda.

The current Takeda UK portfolio comprises of the following medicines.

To download a patient information leaflet (PIL) and a summary of product characteristics (SmPC) for each medicine, simply follow the links within the expandable table below. 

If you are a member of the public requiring advice or information on your own medical condition or treatments listed below please contact your own doctor or NHS Choices in the first instance.  

BUCCOLAM 2.5 mg, 5 mg, 7.5 mg and 10 mg Oromucosal Solution Alert

Please click here for for information and guidance for healthcare professionals regarding the Buccolam tip-cap issue and correct use of the product.

Name

Summary of Product Characteristics Patient Information Leaflet

Actos 15 mg, 30 mg, 45 mg tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Adcetris 50 mg powder for concentrate for solution for infusion

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Advate 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU and 3000 IU powder and solvent for solution for injection 2 ml water – Baxject II

Summary of product characteristics SmPC Patient Information leaflet PIL

Advate 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU and 3000 IU powder and solvent for solution for injection 5 ml water – Baxject II

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Adynovi 1000 IU powder and solvent for solution for injection 2 ml solvent

Summary of product characteristics SmPC Patient Information leaflet PIL

Adynovi 1000 IU powder and solvent for solution for injection 5 ml solvent

Summary of product characteristics SmPC Patient Information leaflet PIL

Adynovi 2000 IU powder and solvent for solution for injection 5 ml solvent

Summary of product characteristics SmPC Patient Information leaflet PIL

Adynovi 250 IU powder and solvent for solution for injection 2 ml solvent

Summary of product characteristics SmPC Patient Information leaflet PIL

Adynovi 250 IU powder and solvent for solution for injection 5 ml solvent

Summary of product characteristics SmPC Patient Information leaflet PIL

Adynovi 500 IU powder and solvent for solution for injection 2 ml solvent

Summary of product characteristics SmPC Patient Information leaflet PIL

Adynovi 500 IU powder and solvent for solution for injection 5 ml solvent

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet Risk Materials
Alofisel 5 million cells/mL suspension for injection Summary of product characteristics SmPC Patient Information leaflet PIL Risk materials

Name

Summary of Product Characteristics Patient Information Leaflet Risk Materials

Alunbrig 30 mg, 90 mg, 180 mg film-coated tablets

Summary of product characteristics SmPC Patient Information leaflet PIL Risk materials

Name

Summary of Product Characteristics Patient Information Leaflet

Amias 2 mg, 4 mg, 8 mg, 16 mg, 32 mg tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

 

Name

Summary of Product Characteristics Patient Information Leaflet Risk materials

Buccolam 2.5 mg oromucosal solution

Summary of product characteristics SmPC Patient Information Leaflet PIL Risk materials

Buccolam 5 mg oromucosal solution

Summary of product characteristics SmPC Patient Information leaflet PIL Risk materials

Buccolam 7.5 mg oromucosal solution

Summary of product characteristics SmPC Patient Information leaflet PIL Risk materials

Buccolam 10 mg oromucosal solution

Summary of product characteristics SmPC Patient Information leaflet PIL Risk materials

Name

Summary of Product Characteristics Patient Information Leaflet

Calcichew 500 mg chewable tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Calcichew D3 chewable tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Calcichew Forte chewable tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Calcichew D3 1000 mg/800 IU once daily chewable tablets 

Summary of product characteristics SmPC Patient Information leaflet PIL

Calcichew D3 Forte chewable tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Ceprotin 1000 IU powder and solvent for solution for injection Summary of product characteristics SmPC Patient Information leaflet PIL

Ceprotin 500 IU powder and solvent for solution for injection

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet Risk materials

Cinryze 500 IU powder and solvent for solution for injection

Summary of product characteristics SmPC Patient Information leaflet PIL Risk materials

Name

Summary of Product Characteristics Patient Information Leaflet

Competact 15 mg/850 mg film-coated tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Condyline 0.5% w/v Cutaneous Solution

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Cuvitru 200 mg/ml solution for subcutaneous injection

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Edarbi 20 mg, 40 mg, 80 mg tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Elaprase 2 mg/ml concentrate for solution for infusion

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Entyvio 300 mg powder for concentrate for solution for infusion Summary of product characteristics SmPC Patient Information leaflet PIL
Entyvio 108 mg solution for injection in pre-filled syringe Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Equasym XL 10 mg modified-release capsules, hard Summary of product characteristics SmPC Patient Information leaflet PIL
Equasym XL 20 mg modified-release capsules, hard Summary of product characteristics SmPC Patient Information leaflet PIL
Equasym XL 30 mg modified-release capsules, hard Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

FEIBA 25 U/ml powder and solvent for solution for infusion

Summary of product characteristics SmPC Patient Information leaflet PIL

FEIBA 50 U/ml powder and solvent for solution for infusion

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Firazyr 30 mg solution for injection in pre-filled syringe Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Flexbumin 200 g/l solution for infusion Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Fosrenol 500 mg chewable tablets Summary of product characteristics SmPC Patient Information leaflet PIL
Fosrenol 750 mg chewable tablets Summary of product characteristics SmPC Patient Information leaflet PIL
Fosrenol 1000 mg chewable tablets Summary of product characteristics SmPC Patient Information leaflet PIL
Fosrenol 750 mg oral powder Summary of product characteristics SmPC Patient Information leaflet PIL
Fosrenol 1000 mg oral powder Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Gammagard S/D 5 g powder and solvent for solution for infusion Summary of product characteristics SmPC Patient Information leaflet PIL
Gammagard S/D 10 g powder and solvent for solution for infusion Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
HyQvia 100 mg/ml solution for infusion for subcutaneous use Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet Risk Materials

Instanyl 50 mcg nasal spray, solution in single-dose container

Summary of product characteristics SmPC Patient Information leaflet PIL Risk materials

Instanyl 100 mcg nasal spray, solution in single-dose container

Summary of product characteristics SmPC Patient Information leaflet PIL Risk materials

Instanyl 200 mcg nasal spray, solution in single-dose container

Summary of product characteristics SmPC Patient Information leaflet PIL Risk materials

Name

Summary of Product Characteristics Patient Information Leaflet

Intuniv® 1 mg prolonged-release tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Intuniv® 2 mg prolonged-release tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Intuniv® 3 mg prolonged-release tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Intuniv® 4 mg prolonged-release tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Kiovig 100 mg/ml solution for infusion Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet Risk Materials

Matrifen 12 micrograms/hour transdermal patch

Summary of product characteristics SmPC Patient Information leaflet PIL Risk materials

Matrifen 25 micrograms/hour transdermal patch

Summary of product characteristics SmPC Patient Information leaflet PIL Risk materials

Matrifen 50 micrograms/hour transdermal patch

Summary of product characteristics SmPC Patient Information leaflet PIL Risk materials

Matrifen 75 micrograms/hour transdermal patch

Summary of product characteristics SmPC Patient Information leaflet PIL Risk materials

Matrifen 100 micrograms/hour transdermal patch

Summary of product characteristics SmPC Patient Information leaflet PIL Risk materials

Name

Summary of Product Characteristics Patient Information Leaflet

Mepact 4 mg powder for suspension for infusion

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Mezavant XL 1200mg, gastro-resistant, prolonged release tablets. Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Natpar 25 micrograms/dose powder and solvent for solution for injection Summary of product characteristics SmPC Patient Information leaflet PIL
Natpar 50 micrograms/dose powder and solvent for solution for injection Summary of product characteristics SmPC Patient Information leaflet PIL
Natpar 75 micrograms/dose powder and solvent for solution for injection Summary of product characteristics SmPC Patient Information leaflet PIL
Natpar 100 micrograms/dose powder and solvent for solution for injection Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Ninlaro 2.3 mg hard capsules

Summary of product characteristics SmPC Patient Information leaflet PIL

Ninlaro 3 mg hard capsules

Summary of product characteristics SmPC Patient Information leaflet PIL

Ninlaro 4 mg hard capsules

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Obizur 500 U powder and solvent for solution for injection Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Plenadren 5 mg modified-release tablets Summary of product characteristics SmPC Patient Information leaflet PIL
Plenadren 20 mg modified-release tablets Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Prostap 3 DCS 11.25 mg powder and solvent for 
prolonged-release suspension for injection in pre-filled syringe

Summary of product characteristics SmPC Patient Information leaflet PIL

Prostap SR DCS 3.75 mg powder and solvent for 
prolonged-release suspension for injection in pre-filled syringe

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Prothromplex Total 600 IU powder and solvent for solution for injection

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Protium 40 mg i.v. powder for solution for injection

Summary of product characteristics SmPC Patient Information leaflet PIL

Pantoprazole 20 mg gastro-resistant tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Pantoprazole 40 mg gastro-resistant tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Reminyl 4 mg/ml oral solution Summary of product characteristics SmPC Patient Information leaflet PIL
Reminyl XL 8 mg prolonged-release capsules, hard Summary of product characteristics SmPC Patient Information leaflet PIL
Reminyl XL 16 mg prolonged-release capsules, hard Summary of product characteristics SmPC Patient Information leaflet PIL
Reminyl XL 24 mg prolonged-release capsules, hard Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Replagal 1 mg/ml concentrate for solution for infusion Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Resolor 1mg film-coated tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Resolor 2mg film-coated tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Revestive 1.25 mg powder and solvent for solution for injection

Summary of product characteristics SmPC Patient Information leaflet PIL

Revestive 5 mg powder and solvent for solution for injection

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Rixubis 250 IU powder and solvent for solution for injection Summary of product characteristics SmPC Patient Information leaflet PIL
Rixubis 500 IU powder and solvent for solution for injection Summary of product characteristics SmPC Patient Information leaflet PIL
Rixubis 1000 IU powder and solvent for solution for injection Summary of product characteristics SmPC Patient Information leaflet PIL
Rixubis 2000 IU powder and solvent for solution for injection Summary of product characteristics SmPC Patient Information leaflet PIL
Rixubis 3000 IU powder and solvent for solution for injection Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Subcuvia 160 g/l Solution for Injection

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
TachoSil sealant matrix Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Takhzyro 300 mg solution for injection

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Veyvondi 1300 IU powder and solvent for solution for injection

Summary of product characteristics SmPC Patient Information leaflet PIL

Veyvondi 650 IU powder and solvent for solution for injection

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Vipdomet 12.5 mg/1000 mg film-coated tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Vipidia 6.25 mg film-coated tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Vipidia 12.5 mg film-coated tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Vipidia 25 mg film-coated tablets

Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet
Vpriv 400 Units powder for solution for infusion Summary of product characteristics SmPC Patient Information leaflet PIL

Name

Summary of Product Characteristics Patient Information Leaflet

Xagrid 0.5mg hard capsule

Summary of product characteristics SmPC Patient Information leaflet PIL

The black triangle denotes this medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.  By reporting side effects you can help provide more information on the safety of this medicine.

Adverse events should also be reported to Takeda UK Ltd:

Legacy-Takeda products - DSO-UK@takeda.com
Legacy-Shire products - drugsafety@shire.com 

 

Medical Information

Our medical information service is intended to provide information on our products to Healthcare Professionals.  For contact information, please view our Contact us page

 

 

UK/WBC/1707/0002d(4)

Date of Preparation: May 2020